ProCE Banner Activity

Phase Ib MMY1001: Daratumumab Plus Pom/Dex in Patients With R/R MM

Slideset Download
Conference Coverage
In this early analysis, combining daratumumab with pomalidomide/dexamethasone showed promising responses in heavily pretreated patients and was tolerable.

Released: December 12, 2015

Expiration: December 10, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen